Zenas BioPharma (NASDAQ:ZBIO) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a research report released on Monday morning,Benzinga reports. The firm currently has a $45.00 target price on the stock.

A number of other equities analysts have also recently commented on ZBIO. Morgan Stanley raised their target price on Zenas BioPharma from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Jefferies Financial Group reissued a “buy” rating and issued a $52.00 price objective on shares of Zenas BioPharma in a research note on Monday, October 27th. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 15th. Finally, Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.29.

Zenas BioPharma Stock Up 17.1%

Zenas BioPharma stock opened at $42.33 on Monday. The company has a market capitalization of $2.27 billion, a PE ratio of -5.99 and a beta of -1.62. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. Zenas BioPharma has a fifty-two week low of $5.83 and a fifty-two week high of $42.99. The firm has a 50 day moving average price of $33.79 and a 200 day moving average price of $22.17.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Transactions at Zenas BioPharma

In other Zenas BioPharma news, major shareholder Sr One Capital Management, Llc acquired 126,315 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were acquired at an average price of $19.00 per share, for a total transaction of $2,399,985.00. Following the acquisition, the insider owned 1,917,895 shares in the company, valued at $36,440,005. The trade was a 7.05% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Patrick G. Enright bought 105,265 shares of the business’s stock in a transaction dated Thursday, October 9th. The shares were acquired at an average cost of $19.00 per share, for a total transaction of $2,000,035.00. Following the transaction, the director directly owned 1,832,669 shares in the company, valued at approximately $34,820,711. This represents a 6.09% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 923,035 shares of company stock valued at $17,628,163 over the last ninety days. Company insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several institutional investors have recently modified their holdings of the stock. Nuveen LLC purchased a new position in shares of Zenas BioPharma in the 1st quarter valued at $250,000. PNC Financial Services Group Inc. boosted its stake in Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after acquiring an additional 2,679 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Zenas BioPharma by 13.9% during the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock worth $128,000 after purchasing an additional 1,607 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Zenas BioPharma by 71.3% during the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after purchasing an additional 8,207 shares in the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.